LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process
May 31 2023 - 8:30AM
Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY®
Robotic Surgical System, the first single-use endovascular surgical
robotic system, announces that an additional milestone was achieved
when medical professionals experienced the Company's LIBERTY
Robotic Surgical System as part of a formative study. The study was
designed to enable medical professionals, including physicians and
Cath-lab technicians, to use and experience LIBERTY in a real-use
simulated environment.
The study was performed and managed by experts
from a company specializing in conducting Human Factors and
Usability Engineering tests of medical devices.
The study included five teams, each consisting
of an interventional radiologist and a Cath-Lab technician and
simulated the expected clinical setup and use of the LIBERTY®
Robotic Surgical System. All participants were successfully trained
on the system prior to their participation and the study validated
that the LIBERTY Robotic Surgical System operation and setup are
intuitive.
Analysis and data from the study exhibited high
subjective grading both by the physicians and the technicians, with
no comments made on the designed operative flow.
“Educating and establishing close relationships
with our target audience enables the Company to gain valuable
feedback and increase awareness to our unique system. In parallel
to our regulatory and pre-clinical efforts, we invest in receiving
endorsements from leading experts and institutes which we believe
will allow us to leverage our path to the clinical stages and later
on to the market," commented Eyal Morag, Chief Medical Officer.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body. The LIBERTY® Robotic Surgical System aims to improve
the way surgical robotics are being used in endovascular procedures
today, by eliminating the need for large, cumbersome, and expensive
capital equipment, while reducing radiation exposure and physician
strain. The Company believes the LIBERTY® Robotic Surgical System’s
remote operation has the potential to be the first system to
democratize endovascular interventional procedures. Further
information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
LIBERTY®, the outcome of its studies to evaluate LIBERTY®, whether
the Company’s core business focus program and cost reduction plan
are sufficient to enable the Company to continue to focus on its
LIBERTY technology while it seeks additional working capital, any
failure or inability to recruit physicians and clinicians to serve
as primary investigators to conduct regulatory studies which could
adversely affect or delay such studies, uncertainty in the results
of pre-clinical and clinical trials or regulatory pathways and
regulatory approvals, uncertainty resulting from the COVID-19
pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC), which are available
on the SEC’s web site at www.sec.gov. Microbot Medical disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
Investor Contact:
Michal Efraty+972-(0)52-3044404IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Oct 2023 to Oct 2024